Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at B.Riley/FBR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $211.54 -0.2%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Join SI Premium – FREE
B.Riley/FBR analyst David Buck lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $219.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crown Castle (CCI) PT Lowered to $91 at BMO Capital Following Mixed Results
- Six Flags Entertainment (FUN) PT Lowered to $14 at Citizens - 'One of the Worst-Performing' Consumer Stocks
- Capital Clean Energy Carriers Corp. (CCEC) PT Lowered to $22 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
David BuckSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
